Current Report Filing (8-k)
May 01 2020 - 7:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
April 30, 2020
Idera Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other
Jurisdiction of
Incorporation)
|
001-31918
(Commission File
Number)
|
04-3072298
(I.R.S. Employer
Identification No.)
|
505 Eagleview Blvd., Suite 212
|
|
|
Exton, Pennsylvania
|
|
19341
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (484) 348-1600
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).
|
Securities registered pursuant to Section 12(b) of the Exchange
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
IDRA
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On April 30, 2020, Idera Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing the Company’s financial results for the quarter ended March 31, 2020. As set forth below,
the Company is furnishing the press release as Exhibit 99.1 to this Current Report on Form 8-K.
|
Item 7.01
|
Regulation FD Disclosure.
|
On May 1, 2020, the Company issued a press release, a copy of
which is attached hereto as Exhibit 99.2 related to the change to the location of the Company’s 2020 annual meeting of stockholders
(the “Annual Meeting”). The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached
Exhibit 99.2 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be
deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of
any general incorporation language in such filing.
|
Item 8.01.
|
Other Information.
|
Change to Virtual Annual Meeting
On May 1, 2020, the Company announced that, due to the public
health impact of the coronavirus (COVID-19) pandemic, the location of the Annual Meeting has been changed and will be held in a
virtual meeting format only. As previously announced, the Annual Meeting will be held on Tuesday, May 12, 2020 at 9:00 a.m. Eastern
Time. The following sets forth access information to attend the Annual Meeting:
Conference Call Access: (844) 882-7837 (U.S.)
or +1 (574) 990-9824 (international);
Conference Code: 7877966
Webcast Access: https://edge.media-server.com/mmc/p/8uhpyq28
Further information regarding this change to the location of
the Annual Meeting can be found in the proxy supplement filed by the Company with the Securities and Exchange Commission on May 1, 2020.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IDERA
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Bryant D. Lim
|
|
|
Bryant
D. Lim
|
|
|
Senior
V.P., General Counsel
|
Dated: May 1, 2020
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2024 to May 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Idera Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Idera Pharmaceuticals, Inc. News Articles